Skip to main content

Artificial Intelligence able to identify potentially life-saving antibiotics

| News

Artificial Intelligence able to identify potentially life-saving antibiotics


A computer algorithm has identified antibiotics that that are still effective against infections in which multi-resistant germs are present. University Hospital Basel and the Basel-based Department of Biosystems Science and Engineering at the Swiss Federal Institute of Technology in Zurich will initially put their new method to the test as part of a clinical trial.

Study leader Prof. Adrian Egli with his colleague Aline Cuénod in the laboratory medicine department of the University Hospital Basel (img: USB)

Researchers from University Hospital Basel (USB) and the Department of Biosystems Science and Engineering (D-BSSE) at the Swiss Federal Institute of Technology in Zurich (ETH) in Basel are using innovative computer algorithms in the fight against antibiotic-resistant bacteria. With this new method, the researchers can identify characteristics of antibiotic resistance in germs up to 24 hours earlier. This means that it is clear sooner rather than later which antibiotics can still help patients. The cantons of Basel-Stadt and Basel-Landschaft offered financial support for this research project.

“In cases of severe infection, the time until optimal therapy can be the difference between life and death. A quick and precise diagnosis is extremely important here”, comments Professor Adrian Egli, Head of the Clinical Bacteriology department at USB and study director, in a press release.

Larger clinical study will follow

The study team linked 300,000 mass spectrometry data samples from individual bacteria from four laboratories in north-western Switzerland with the results of antibiotic resistance tests in the laboratory. “Intelligent computer algorithms look for patterns in the data that distinguish bacteria with and without resistance from one another”, explains Caroline Weis, PhD student at the D-BSSE at ETH Zurich in Basel and lead author of the study.

The researchers have published their method in the latest edition of the specialist journal “Nature Medicine”. It must now be confirmed in a larger clinical study carried out as part of everyday hospital operations. Plans are already in place for this to take place at USB.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

biGENIUS receives 2 million euros for new cloud product

Software company biGENIUS, based in the Basel Area, has secured financing of 2 million euros. This funding was granted following...
Read More

Opterion Health secures investment of 6.5 million Swiss francs

Opterion Health has raised a total of 6.5 million Swiss francs as part of a financing round. The company, which...
Read More

TOLREMO receives 39 million US dollars in investments

TOLREMO Therapeutics has concluded a series A funding round with 39 million US dollars. The biotech company based in Basel...
Read More

Mazars opens tenth Swiss office in Basel

Mazars is now also present in Basel with a subsidiary as of September 1. This is the tenth Swiss location...
Read More

Medtech in Switzerland – bringing together traditional skills and hightech industry

How the intersection of traditional and novel skillsets in the Jura area is propelling Switzerland into a new era of...
Read More

Fondation Botnar supporting further research into pediatric health

The Basel-based Botnar Research Centre for Child Health has received a further donation of 50 million Swiss francs from the...
Read More

Do you have a question? We'd like to hear from you.